---
title: "羅氏通過要約收購購買 89Bio, Inc 的股份"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263440706.md"
description: "巴塞爾，2025 年 10 月 30 日- 羅氏（SIX: RO, ROG. OTCQX: RHHBY）今天宣佈，羅氏全資子公司 Bluefin Merger Subsidiary, Inc.已接受所有有效提交且未有效撤回的股份的付款，作為其對所有已發行普通股的收購要約的一部分"
datetime: "2025-10-30T07:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263440706.md)
  - [en](https://longbridge.com/en/news/263440706.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263440706.md)
---

# 羅氏通過要約收購購買 89Bio, Inc 的股份

Basel, 30 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common ...

### 相關股票

- [ETNB.US](https://longbridge.com/zh-HK/quote/ETNB.US.md)
- [RHHBY.US](https://longbridge.com/zh-HK/quote/RHHBY.US.md)

## 相關資訊與研究

- [羅氏(ADR)與藥品專利池簽署協議，擴大流感藥物可及性](https://longbridge.com/zh-HK/news/286796802.md)
- [川普效應 瑞士企業限縮與調整 DEI 措施](https://longbridge.com/zh-HK/news/283831792.md)
- [FOMO2026 ：全球創新藥大變局，看懂的人還不多](https://longbridge.com/zh-HK/news/286487435.md)
- [FDA 批准了 Genentech 的 Tecentriq 用於 ctDNA 指導治療的輔助性肌肉浸潤性膀胱癌 | 羅氏 (ADR) 股票新聞](https://longbridge.com/zh-HK/news/286594661.md)
- [BeOne 公司的 Venclexta 競爭藥物 Beqalzi 獲得 FDA 批准](https://longbridge.com/zh-HK/news/286315985.md)